Free Delivery Over $100
|
|
|||
|
||||
OverviewAdvancements in the management of gastrointestinal and hepatic diseases have been possible through a better understanding of their underlying mechanisms. For instance, the development of direct-acting antivirals has been achieved through improved knowledge of HCV infection. The incidences of peptic disease and stomach cancer have been reduced through efforts to decrease H. pylori infection, increased use of proton-pump inhibitors, and greater accessibility to gastroscopies. Targeted therapies such as anti-TNF, anti-IL12/23, and anti-JAK have been developed based on an understanding of the inflammatory pathways involved in inflammatory bowel disease. Finally, increased knowledge of the microbiota will lead to novel clinical applications beyond gut-related diseases. Full Product DetailsAuthor: Davide Giuseppe Ribaldone , Gian Paolo CavigliaPublisher: Mdpi AG Imprint: Mdpi AG Dimensions: Width: 17.00cm , Height: 2.40cm , Length: 24.40cm Weight: 0.807kg ISBN: 9783725801299ISBN 10: 3725801290 Pages: 282 Publication Date: 09 February 2024 Audience: General/trade , General Format: Hardback Publisher's Status: Active Availability: In stock  We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
